{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:19:37Z","timestamp":1778001577195,"version":"3.51.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Calcimimetic treatment of secondary hyperparathyroidism in chronic dialysis patients is often followed by hypocalcemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated the frequency, predictors, consequences and therapeutic responses following cinacalcet-induced hypocalcemia in an incident European hemodialysis cohort of 1068 patients with a cinacalcet prescription.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 905 normocalcemic patients initiating cinacalcet, 67% developed hypocalcemia within 12\u00a0months: 68% mild, 23% moderate, 9% severe. Compared to persistently normocalcemic patients, those with severe hypocalcemia were more often diabetic, overweight, had cardiovascular disease, shorter dialysis vintage, used a catheter dialysis access, had fewer active vitamin-D sterols, and exhibited higher CRP and iPTH and lower calcium levels. Multivariate predictors of hypocalcemia included a catheter for vascular access, low albumin and high iPTH. Generally, no therapeutic intervention to prevent hypocalcemia was taken prior to cinacalcet initiation. After the hypocalcemic event, the most common clinical response was no change of the dialysis or medical regimen. Following the hypocalcemic event, iPTH remained low even in those with severe hypocalcemia. The number of deaths and cardiovascular events did not differ between patients with and without hypocalcemia within six months following cinacalcet initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Two-thirds of cinacalcet initiated patients experienced hypocalcaemia with 9% being severe. Hypocalcemia was mostly asymptomatic, transient (with and without targeted intervention to correct it) and not associated with an increase in cardiovascular events or deaths.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-019-00686-z","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T13:02:51Z","timestamp":1576587771000},"page":"803-816","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes"],"prefix":"10.1093","volume":"33","author":[{"given":"Karly S.","family":"Louie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clement","family":"Erhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Stenvinkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Fouqueray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"issue":"4","key":"686_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6(4):913\u2013921. https:\/\/doi.org\/10.2215\/CJN.06040710","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"686_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB (2017) Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters. Kidney Int 92(1):26\u201336. https:\/\/doi.org\/10.1016\/j.kint.2017.04.006","journal-title":"Kidney Int"},{"issue":"1","key":"686_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","volume":"132","author":"SM Moe","year":"2015","unstructured":"Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drueke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J, Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators (2015) Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation 132(1):27\u201339. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013876","journal-title":"Circulation"},{"issue":"15","key":"686_CR4","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350(15):1516\u20131525. https:\/\/doi.org\/10.1056\/NEJMoa031633","journal-title":"N Engl J Med"},{"issue":"4","key":"686_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000350213","volume":"37","author":"RD Kilpatrick","year":"2013","unstructured":"Kilpatrick RD, Newsome BB, Zaun D, Liu J, Solid CA, Nieman K, St Peter WL (2013) Evaluating real-world use of cinacalcet and biochemical response to therapy in US hemodialysis patients. Am J Nephrol 37(4):389\u2013398. https:\/\/doi.org\/10.1159\/000350213","journal-title":"Am J Nephrol"},{"issue":"1","key":"686_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2215\/CJN.03591006","volume":"3","author":"P Messa","year":"2008","unstructured":"Messa P, Macario F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazao JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F (2008) The OPTIMA study: assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3(1):36\u201345. https:\/\/doi.org\/10.2215\/CJN.03591006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"686_CR7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.2215\/CJN.05241008","volume":"4","author":"WL St Peter","year":"2009","unstructured":"St Peter WL, Li Q, Liu J, Persky M, Nieman K, Arko C, Block GA (2009) Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol 4(2):354\u2013360. https:\/\/doi.org\/10.2215\/CJN.05241008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"686_CR8","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1093\/ndt\/gfp144","volume":"24","author":"P Urena","year":"2009","unstructured":"Urena P, Jacobson SH, Zitt E, Vervloet M, Malberti F, Ashman N, Leavey S, Rix M, Os I, Saha H, Ryba M, Bencova V, Banos A, Zani V, Fouque D (2009) Cinacalcet and achievement of the NKF\/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice\u2013the ECHO observational study. Nephrol Dial Transplant 24(9):2852\u20132859. https:\/\/doi.org\/10.1093\/ndt\/gfp144","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"686_CR9","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/ndt\/gfs568","volume":"28","author":"P Urena-Torres","year":"2013","unstructured":"Urena-Torres P, Bridges I, Christiano C, Cournoyer SH, Cooper K, Farouk M, Kopyt NP, Rodriguez M, Zehnder D, Covic A (2013) Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrol Dial Transplant 28(5):1241\u20131254. https:\/\/doi.org\/10.1093\/ndt\/gfs568","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"686_CR10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0272-6386(97)90131-1","volume":"29","author":"DN Cruz","year":"1997","unstructured":"Cruz DN, Perazella MA (1997) Biochemical aberrations in a dialysis patient following parathyroidectomy. Am J Kidney Dis 29(5):759\u2013762","journal-title":"Am J Kidney Dis"},{"key":"686_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.12.014","author":"J Floege","year":"2018","unstructured":"Floege J, Tsirtsonis K, Iles J, Drueke TB, Chertow GM, Parfrey P (2018) Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2017.12.014","journal-title":"Kidney Int"},{"issue":"6","key":"686_CR12","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.kint.2018.01.038","volume":"93","author":"P Evenepoel","year":"2018","unstructured":"Evenepoel P, Shroff R (2018) Facing cinacalcet-induced hypocalcemia: sit back and relax? Kidney Int 93(6):1275\u20131277. https:\/\/doi.org\/10.1016\/j.kint.2018.01.038","journal-title":"Kidney Int"},{"issue":"2","key":"686_CR13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.nefro.2015.10.006","volume":"36","author":"AL de Francisco","year":"2016","unstructured":"de Francisco AL, Gillespie IA, Gioni I, Floege J, Kronenberg F, Marcelli D, Wheeler DC, Froissart M, Drueke TB, Cllaborators AROSC (2016) Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism. Nefrologia 36(2):164\u2013175. https:\/\/doi.org\/10.1016\/j.nefro.2015.10.006","journal-title":"Nefrologia"},{"issue":"5","key":"686_CR14","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ki.2014.419","volume":"87","author":"J Floege","year":"2015","unstructured":"Floege J, Gillespie IA, Kronenberg F, Anker SD, Gioni I, Richards S, Pisoni RL, Robinson BM, Marcelli D, Froissart M, Eckardt KU (2015) Development and validation of a predictive mortality risk score from a European hemodialysis cohort. Kidney Int 87(5):996\u20131008. https:\/\/doi.org\/10.1038\/ki.2014.419","journal-title":"Kidney Int"},{"issue":"11","key":"686_CR15","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1093\/ndt\/15.11.1841","volume":"15","author":"CM Clase","year":"2000","unstructured":"Clase CM, Norman GL, Beecroft ML, Churchill DN (2000) Albumin-corrected calcium and ionized calcium in stable haemodialysis patients. Nephrol Dial Transplant 15(11):1841\u20131846","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"686_CR16","doi-asserted-by":"publisher","first-page":"e017703","DOI":"10.1136\/bmjopen-2017-017703","volume":"8","author":"IA Lian","year":"2018","unstructured":"Lian IA, Asberg A (2018) Should total calcium be adjusted for albumin? A retrospective observational study of laboratory data from central Norway. BMJ Open 8(4):e017703. https:\/\/doi.org\/10.1136\/bmjopen-2017-017703","journal-title":"BMJ Open"},{"issue":"3","key":"686_CR17","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1681\/ASN.2004060512","volume":"16","author":"JS Lindberg","year":"2005","unstructured":"Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW (2005) Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 16(3):800\u2013807. https:\/\/doi.org\/10.1681\/ASN.2004060512","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"686_CR18","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/pds.3845","volume":"24","author":"SM Brunelli","year":"2015","unstructured":"Brunelli SM, Dluzniewski PJ, Cooper K, Do TP, Sibbel S, Bradbury BD (2015) Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation. Pharmacoepidemiol Drug Saf 24(10):1058\u20131067. https:\/\/doi.org\/10.1002\/pds.3845","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"686_CR19","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/jbmr.309","volume":"26","author":"HH Malluche","year":"2011","unstructured":"Malluche HH, Mawad HW, Monier-Faugere MC (2011) Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 26(6):1368\u20131376. https:\/\/doi.org\/10.1002\/jbmr.309","journal-title":"J Bone Miner Res"},{"issue":"26","key":"686_CR20","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"Evolve Trial Investigators","year":"2012","unstructured":"Investigators Evolve Trial, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367(26):2482\u20132494. https:\/\/doi.org\/10.1056\/NEJMoa1205624","journal-title":"N Engl J Med"},{"issue":"6","key":"686_CR21","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2215\/CJN.07050714","volume":"10","author":"JB Wetmore","year":"2015","unstructured":"Wetmore JB, Gurevich K, Sprague S, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K (2015) A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol 10(6):1031\u20131040. https:\/\/doi.org\/10.2215\/CJN.07050714","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"686_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00228-015-1989-6","volume":"72","author":"T Novick","year":"2016","unstructured":"Novick T, McMahon BA, Berliner A, Jaar BG (2016) Cinacalcet-associated severe hypocalcemia resulting in torsades de pointes and cardiac arrest: a case for caution. Eur J Clin Pharmacol 72(3):373\u2013375. https:\/\/doi.org\/10.1007\/s00228-015-1989-6","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"686_CR23","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.nephro.2012.03.003","volume":"8","author":"F Simon","year":"2012","unstructured":"Simon F, Bertrand Q, Pirson Y, Flamion B, Loute G (2012) Potentialisation of hyperkalemia effects by cinacalcet-induced hypocalcemia on dialysis. Nephrol Ther 8(6):476\u2013480. https:\/\/doi.org\/10.1016\/j.nephro.2012.03.003","journal-title":"Nephrol Ther"},{"issue":"1","key":"686_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s13730-017-0284-z","volume":"7","author":"SH Koubar","year":"2018","unstructured":"Koubar SH, Qannus AA, Medawar W, Abu-Alfa AK (2018) Hungry bone syndrome two weeks after starting cinacalcet: a call for caution. CEN Case Rep 7(1):21\u201323. https:\/\/doi.org\/10.1007\/s13730-017-0284-z","journal-title":"CEN Case Rep"},{"issue":"2","key":"686_CR25","doi-asserted-by":"publisher","first-page":"c80","DOI":"10.1159\/000151722","volume":"110","author":"L Viaene","year":"2008","unstructured":"Viaene L, Evenepoel P, Bammens B, Claes K, Kuypers D, Vanrenterghem Y (2008) Calcium requirements after parathyroidectomy in patients with refractory secondary hyperparathyroidism. Nephron Clin Pract 110(2):c80\u2013c85. https:\/\/doi.org\/10.1159\/000151722","journal-title":"Nephron Clin Pract"},{"issue":"8","key":"686_CR26","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1681\/ASN.2007040449","volume":"19","author":"Gauci C, Moranne O, Fouqueray B, de la Faille R, Maruani G, Haymann JP, Jacquot C, Boffa JJ, Flamant M, Rossert J, Urena P, Stengel B, Souberbielle JC, Froissart M, Houillier P, NephroTest Study G","year":"2008","unstructured":"Gauci C, Moranne O, Fouqueray B, de la Faille R, Maruani G, Haymann JP, Jacquot C, Boffa JJ, Flamant M, Rossert J, Urena P, Stengel B, Souberbielle JC, Froissart M, Houillier P, NephroTest Study G (2008) Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol 19(8):1592\u20131598. https:\/\/doi.org\/10.1681\/ASN.2007040449","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"686_CR27","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/ki.2015.117","volume":"88","author":"KU Eckardt","year":"2015","unstructured":"Eckardt KU, Gillespie IA, Kronenberg F, Richards S, Stenvinkel P, Anker SD, Wheeler DC, de Francisco AL, Marcelli D, Froissart M, Floege J, Committee AROS (2015) High cardiovascular event rates occur within the first weeks of starting hemodialysis. Kidney Int 88(5):1117\u20131125. https:\/\/doi.org\/10.1038\/ki.2015.117","journal-title":"Kidney Int"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-019-00686-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40620-019-00686-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-019-00686-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:33Z","timestamp":1777564593000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/33\/4\/803\/8328479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["686"],"URL":"https:\/\/doi.org\/10.1007\/s40620-019-00686-z","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]},"assertion":[{"value":"8 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KL and BF are employees and stockholders of Amgen. CE is an independent contractor providing statistical services to Amgen. DW has received consultancy and speaker fees from Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Janssen, Glaxo Smith Kline, Mundipharam, Napp, Reata and Vifor Fresenius.PS has received consultancy and speaker fees from Reata, Astra Zeneca, Corvidia, Baxter, Astellas and Pfizer. JF has received personal fees from Amgen, Fresenius, Sanofi and Vifor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Data were collected and processed in accordance with local ethical and regulatory requirements for each participating FMC facility.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients, where required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}